New Trials Suggest Radiation May Be Skippable for Some Cancers

What if you could potentially avoid a grueling cancer treatment like radiation therapy and still achieve excellent results? Exciting new clinical trials are suggesting just that for some patients battling rectal cancer and lymphoma, offering hope for reduced toxicity and improved long-term quality of life.

Rethinking Treatment for Rectal Cancer

For locally advanced rectal cancer, the standard treatment often involves a lengthy course of radiation therapy before surgery, followed by chemotherapy. However, a new clinical trial presented at the American Society of Clinical Oncology (ASCO) annual meeting has challenged this approach. Researchers found that rectal cancer patients whose tumors significantly shrink after chemotherapy may be able to safely skip radiation altogether.

Dr. Deb Schrag, the lead researcher, explained the significance: “We can successfully de-escalate treatment of rectal cancer and achieve the same high cure rates — keep patients disease-free with less long-term toxicity.” This “less is more” approach could spare patients from radiation’s harsh side effects, such as damage to bowel, bladder, and sexual function, and reduce the risk of infertility or premature menopause, especially crucial for younger patients.

Omitting Radiation for Lymphoma Patients

Similarly, another trial explored whether radiation is always necessary for lymphoma patients. Researchers discovered that individuals with primary B-cell lymphoma whose cancers respond well to chemotherapy and immunotherapy might not need radiation treatment. In this study, patients who received chemo and immunotherapy alone showed survival rates comparable to those who also received radiation.

Dr. Julie Gralow, ASCO’s chief medical officer, highlighted the long-term impact of radiation, noting that it can lead to substantial cardiac problems later in life. The goal is to “back off on radiation and improve the side effects for the patients” when other effective treatments are available.

The Science Behind the Shift

These findings are driven by significant advancements in chemotherapy, surgical techniques, and imaging. “We’re finding more tumors when they’re smaller and easier to treat,” Dr. Schrag noted, prompting the question of whether radiation could be used more selectively. The rectal cancer trial involved 585 patients on the new regimen versus 543 on the standard care, with disease-free survival rates remaining nearly identical.

Crucially, in the new approach for rectal cancer, over 90% of patients responded to chemotherapy and did not require radiation. Dr. Pamela Kunz, director of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital, called the rectal cancer trial “practice-changing,” emphasizing that sparing select patients from radiation can significantly improve their quality of life without compromising efficacy.

Important Considerations

While these results are incredibly promising, it’s vital to remember that every patient responds differently to treatment. The decision to omit radiation therapy should always be made in consultation with a medical team, considering the specific type and location of cancer, the dosage of radiation, and the patient’s overall health. The findings from the rectal cancer trial have been published in the New England Journal of Medicine and the Journal of Clinical Oncology, while the lymphoma trial results were presented at ASCO.